Form 4 Filing for Aldeyra Therapeutics, Inc.

This filing details a Form 4 submission for Aldeyra Therapeutics, Inc. (ALDX) on March 27, 2026. It reports transactions by Brady Todd C, President and CEO, who is also a director. The transactions include the acquisition of 1,880,510 stock options with a strike price of $1.77, vesting over 48 months, and 632,318 bonus units, which vest over four years and will result in a cash payment based on the closing stock price at the time of vesting or a change of control. Both the stock options and bonus units are directly owned by Mr. Brady. The filing also notes the exercise date for the stock option is subject to a footnote regarding vesting schedules and the expiration date for the bonus units is also tied to a footnote concerning vesting and payment conditions.